Related Experiment Videos

Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial

Shyam Bhakta1, Mark E Dunlap

  • 1Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland, USA.

Cleveland Clinic Journal of Medicine
|September 29, 2004
PubMed

Insights

The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial shows candesartan is a beneficial heart failure treatment. It works as an alternative to ACE inhibitors and is effective when added to existing therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure (HF) management often involves angiotensin-converting enzyme (ACE) inhibitors.
  • Alternative or add-on therapies are needed to improve outcomes in diverse HF populations.
  • Angiotensin-receptor blockers (ARBs) offer a potential therapeutic avenue.

Purpose of the Study:

  • To evaluate the efficacy and safety of candesartan in patients with heart failure.
  • To determine if candesartan is a viable alternative to ACE inhibitors.
  • To assess the benefit of adding candesartan to established ACE inhibitor and beta-blocker regimens.

Main Methods:

  • The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial enrolled patients with heart failure.
  • Participants received candesartan, with comparisons made against placebo or standard care.
  • Subgroup analyses considered patients with and without left ventricular systolic dysfunction.

Main Results:

  • Candesartan demonstrated acceptable tolerability as an alternative to ACE inhibitors.
  • Adding candesartan to ACE inhibitors and beta-blockers provided significant benefits.
  • The positive effects of candesartan were observed across HF patients, irrespective of left ventricular systolic dysfunction.

Conclusions:

  • Candesartan is a safe and effective treatment option for heart failure patients.
  • The addition of candesartan to standard therapy (ACE inhibitors and beta-blockers) improves outcomes.
  • Candesartan offers a valuable therapeutic strategy for a broad spectrum of heart failure patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...